On this episode, we’re covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma.To listen to more podcasts from ASCO, visit asco.org/podcasts. 

On this episode, we’re covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma.To listen to more podcasts from ASCO, visit <a href="https://old-prod.asco.org/news-initiatives/podcasts" rel="nofollow" target="_blank">asco.org/podcasts</a>.

FDA Approvals in Hepatocellular Carcinoma and Multiple Myeloma

On this episode, we’re covering two studies that focused on the effects of mortgage discrimination on cancer care outcomes. The research—in colon and lung cancers—was presented during the 2022 ASCO Quality Care Symposium.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re covering two studies that focused on the effects of mortgage discrimination on cancer care outcomes. The research—in colon and lung cancers—was presented during the 2022 ASCO Quality Care Symposium.To listen to more podcasts from ASCO, visit <a href="https://www.asco.org/news-initiatives/podcasts" rel="nofollow" target="_blank">asco.org/podcasts</a>.

Effects of Mortgage Discrimination on Cancer Care Outcomes

On this episode, we’re highlighting speakers who presented data in skin cancers during the ESMO Congress 2022, including findings on tumor-infiltrating lymphocyte therapy in advanced melanoma, cemiplimab in cutaneous squamous cell carcinoma, and the association of circulating tumor DNA and disease recurrence in patients with later-stage melanoma.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re highlighting speakers who presented data in skin cancers during the ESMO Congress 2022, including findings on tumor-infiltrating lymphocyte therapy in advanced melanoma, cemiplimab in cutaneous squamous cell carcinoma, and the association of circulating tumor DNA and disease recurrence in patients with later-stage melanoma.To listen to more podcasts from ASCO, visit <a href="https://www.asco.org/news-initiatives/podcasts" rel="nofollow" target="_blank">asco.org/podcasts</a>.

ESMO 2022: Updates in Skin Cancer

The 2022 ASCO Quality Care Symposium took place in Chicago over the weekend. On this episode, we’re featuring two speakers who presented data at the meeting: the first focuses on the effects of Medicaid expansion on cancer mortality rates, and the second describes efforts to improve prescribing practices for prophylactic colony stimulating factors in the treatment of neutropenia.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The 2022 ASCO Quality Care Symposium took place in Chicago over the weekend. On this episode, we’re featuring two speakers who presented data at the meeting: the first focuses on the effects of Medicaid expansion on cancer mortality rates, and the second describes efforts to improve prescribing practices for prophylactic colony stimulating factors in the treatment of neutropenia.To listen to more podcasts from ASCO, visit <a href="https://www.asco.org/news-initiatives/podcasts" rel="nofollow" target="_blank">asco.org/podcasts</a>.

Highlights From the 2022 ASCO Quality Care Symposium

On this episode, we’re highlighting speakers who presented data in breast cancer during the ESMO Congress 2022. The first speaker discusses patterns of genomic instability in metastatic breast cancer, and the second touches on oncofertility care for young patients with breast cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re highlighting speakers who presented data in breast cancer during the ESMO Congress 2022. The first speaker discusses patterns of genomic instability in metastatic breast cancer, and the second touches on oncofertility care for young patients with breast cancer.To listen to more podcasts from ASCO, visit <a href="https://www.asco.org/news-initiatives/podcasts" rel="nofollow" target="_blank">asco.org/podcasts</a>.

ESMO 2022: Updates in Breast Cancer

The ESMO Congress 2022 took place in Paris from September 9 to 13. In this episode, we highlight key research presented at the meeting. We’ll first hear from the presenting author of Abstract LBA1 on the effect of air pollutants on the risk of non–small cell lung cancer. Then, we’ll hear from a researcher on the SWOG S1801 team on the benefits of different therapeutic strategies using pembrolizumab in patients with advanced melanoma. Finally, we’ll hear about the results of the IMmotion 010 study of adjuvant atezolizumab for renal cell carcinoma post-nephrectomy.To listen to more podcasts from ASCO, visit asco.org/podcasts.

The ESMO Congress 2022 took place in Paris from September 9 to 13. In this episode, we highlight key research presented at the meeting. We’ll first hear from the presenting author of Abstract LBA1 on the effect of air pollutants on the risk of non–small cell lung cancer. Then, we’ll hear from a researcher on the SWOG S1801 team on the benefits of different therapeutic strategies using pembrolizumab in patients with advanced melanoma. Finally, we’ll hear about the results of the IMmotion 010 study of adjuvant atezolizumab for renal cell carcinoma post-nephrectomy.To listen to more podcasts from ASCO, visit <a href="https://www.asco.org/news-initiatives/podcasts" rel="nofollow" target="_blank">asco.org/podcasts</a>.

Highlights From the ESMO Congress 2022

This week, we’re covering the FDA approval of pemigatinib for patients with myeloid or lymphoid neoplasms and an FGFR1 rearrangement. We’ll also discuss a long-term update from the STAMPEDE trial of radiotherapy in prostate cancer.Coverage of stories discussed this week on ascopost.com:FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 RearrangementLong-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-upTo listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re covering the FDA approval of pemigatinib for patients with myeloid or lymphoid neoplasms and an FGFR1 rearrangement. We’ll also discuss a long-term update from the STAMPEDE trial of radiotherapy in prostate cancer.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/news/august-2022/fda-approves-pemigatinib-for-patients-with-myeloidlymphoid-neoplasms-and-fgfr1-rearrangement/" rel="nofollow" target="_blank">FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and </a><a href="https://ascopost.com/news/august-2022/fda-approves-pemigatinib-for-patients-with-myeloidlymphoid-neoplasms-and-fgfr1-rearrangement/" rel="nofollow" target="_blank">FGFR1</a><a href="https://ascopost.com/news/august-2022/fda-approves-pemigatinib-for-patients-with-myeloidlymphoid-neoplasms-and-fgfr1-rearrangement/" rel="nofollow" target="_blank"> Rearrangement</a><a href="https://ascopost.com/news/august-2022/long-term-benefit-of-radiotherapy-confirmed-in-advanced-prostate-cancer-stampede-trial-follow-up/" rel="nofollow" target="_blank">Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up</a>To listen to more podcasts from ASCO, visit <a href="https://www.asco.org/news-initiatives/podcasts" rel="nofollow" target="_blank">asco.org/podcasts</a>.

FDA Approval of Pemigatinib and Update From the STAMPEDE Trial

In this episode, we’re featuring two speakers presenting data from the European Hematology Association 2022 Congress, focusing on findings in acute myeloid leukemia and diffuse large B-cell lymphoma.To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we’re featuring two speakers presenting data from the European Hematology Association 2022 Congress, focusing on findings in acute myeloid leukemia and diffuse large B-cell lymphoma.To listen to more podcasts from ASCO, visit <a href="https://www.asco.org/news-initiatives/podcasts" rel="nofollow" target="_blank">asco.org/podcasts</a>.

Highlights From the European Hematology Association 2022 Congress

On this episode, we’re featuring discussions about data in colorectal cancer that were presented at the 2022 ASCO Annual Meeting. Dr. Michael Overman, of The University of Texas MD Anderson Cancer Center, speaks with two presenters about guiding therapy with circulating tumor DNA and refining treatment strategies for RAS wild-type metastatic disease.To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re featuring discussions about data in colorectal cancer that were presented at the 2022 ASCO Annual Meeting. Dr. Michael Overman, of The University of Texas MD Anderson Cancer Center, speaks with two presenters about guiding therapy with circulating tumor DNA and refining treatment strategies for RAS wild-type metastatic disease. To listen to more podcasts from ASCO, visit <a href="https://www.asco.org/news-initiatives/podcasts" rel="nofollow" target="_blank">asco.org/podcasts</a>.

ASCO 2022: Conversations in Colorectal Cancer

Dr. Courtney DiNardo, of The University of Texas MD Anderson Cancer Center, sat down with two colleagues at the 2022 ASCO Annual Meeting to discuss data presented in leukemia. On this episode of the podcast, we’re featuring Dr. DiNardo’s conversations.To listen to more podcasts from ASCO, visit asco.org/podcasts.

Dr. Courtney DiNardo, of The University of Texas MD Anderson Cancer Center, sat down with two colleagues at the 2022 ASCO Annual Meeting to discuss data presented in leukemia. On this episode of the podcast, we’re featuring Dr. DiNardo’s conversations.To listen to more podcasts from ASCO, visit <a href="https://www.asco.org/news-initiatives/podcasts" rel="nofollow" target="_blank">asco.org/podcasts</a>.

ASCO 2022: Conversations in Leukemia

News and views from the world of clinical oncology and hematology.

The ASCO Post Podcast

In this episode, we’ll cover three important presentations from the San Antonio Breast Cancer Symposium. The first reports results from the HER2CLIMB trial on tucatinib, capecitabine, and trastuzumab for patients with HER2-positive metastatic breast cancer; the second discusses phase II findings on the activity of a novel HER2-targeting antibody-drug conjugate in HER2-positive metastatic breast cancer; and the third focuses on a postoperative treatment regimen for hormone receptor–positive, HER2-negative primary breast cancer.

In this episode, we’ll cover three important presentations from the San Antonio Breast Cancer Symposium. The first reports results from the HER2CLIMB trial on tucatinib, capecitabine, and trastuzumab for patients with HER2-positive metastatic breast cancer; the second discusses phase II findings on the activity of a novel HER2-targeting antibody-drug conjugate in HER2-positive metastatic breast cancer; and the third focuses on a postoperative treatment regimen for hormone receptor–positive, HER2-negative primary breast cancer.

News From the San Antonio Breast Cancer Symposium

This week, we review a presentation on the benefit of daratumumab across populations with newly diagnosed multiple myeloma. We also talk about a study on racial disparities in colorectal cancer mortality. Lastly, we discuss the FDA’s recent approval of apalutamide in metastatic castration-sensitive prostate cancer.Coverage of stories discussed this week on ascopost.com:Tailoring Upfront Daratumumab Treatment for Some Patients With Multiple MyelomaAACR Disparities: Mortality Rate for Colorectal Cancer Higher for Blacks Than for Whites in Major U.S. CitiesFDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

This week, we review a presentation on the benefit of daratumumab across populations with newly diagnosed multiple myeloma. We also talk about a study on racial disparities in colorectal cancer mortality. Lastly, we discuss the FDA’s recent approval of apalutamide in metastatic castration-sensitive prostate cancer. Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/issues/september-25-2019/tailoring-upfront-daratumumab-treatment-for-some-patients-with-multiple-myeloma/" rel="nofollow" target="_blank">Tailoring Upfront Daratumumab Treatment for Some Patients With Multiple Myeloma</a><a href="https://ascopost.com/news/september-2019/mortality-rate-for-colorectal-cancer-higher-for-blacks-than-for-whites-in-major-us-cities/" rel="nofollow" target="_blank">AACR Disparities: Mortality Rate for Colorectal Cancer Higher for Blacks Than for Whites in Major U.S. Cities</a><a href="https://ascopost.com/news/september-2019/fda-approves-apalutamide-for-metastatic-castration-sensitive-prostate-cancer/" rel="nofollow" target="_blank">FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer</a>

Benefit of Daratumumab Across Populations With Newly Diagnosed Multiple Myeloma

We discuss two studies on colorectal cancer that were presented at the ESMO World Congress on Gastrointestinal Cancer. We also talk about a recently published study on the prevalence of pain among cancer survivors in the U.S.Coverage of stories discussed this week on ascopost.com:BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal CancerREARRANGE Trial Examines Flexible Regorafenib Dosing in Refractory Metastatic Colorectal CancerChronic Pain in U.S. Cancer Survivors

We discuss two studies on colorectal cancer that were presented at the ESMO World Congress on Gastrointestinal Cancer. We also talk about a recently published study on the prevalence of pain among cancer survivors in the U.S.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/News/60227" rel="nofollow" target="_blank">BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in </a><a href="https://ascopost.com/News/60227" rel="nofollow" target="_blank">BRAF </a><a href="https://ascopost.com/News/60227" rel="nofollow" target="_blank">V600E–Mutated Metastatic Colorectal Cancer</a><a href="https://ascopost.com/News/60226" rel="nofollow" target="_blank">REARRANGE Trial Examines Flexible Regorafenib Dosing in Refractory Metastatic Colorectal Cancer</a><a href="https://ascopost.com/News/60223" rel="nofollow" target="_blank">Chronic Pain in U.S. Cancer Survivors</a>

ESMO World GI: Findings From the BEACON CRC Trial and More

We’ll start with a trial focused on the sequence of therapies for metastatic, castration-resistant prostate cancer. Then, we’ll move on to an abstract presented at a recent American Heart Association meeting about the link between increased cardiovascular disease risk and increased cancer risk. Lastly, we’ll give you an update about the latest step in the confirmation process for Dr. Stephen Hahn, the oncologist nominated to be the next FDA Commissioner.Coverage of stories discussed this week on ascopost.com:Sequencing of Enzalutamide and Abiraterone Acetate in Metastatic Castration-Resistant Prostate CancerCardiovascular Disease Risk May Be Associated With Cancer Risk

We’ll start with a trial focused on the sequence of therapies for metastatic, castration-resistant prostate cancer. Then, we’ll move on to an abstract presented at a recent American Heart Association meeting about the link between increased cardiovascular disease risk and increased cancer risk. Lastly, we’ll give you an update about the latest step in the confirmation process for Dr. Stephen Hahn, the oncologist nominated to be the next FDA Commissioner.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/news/december-2019/sequencing-of-enzalutamide-and-abiraterone-acetate-in-metastatic-castration-resistant-prostate-cancer/" rel="nofollow" target="_blank">Sequencing of Enzalutamide and Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer</a><a href="https://ascopost.com/news/december-2019/cardiovascular-disease-risk-may-be-associated-with-cancer-risk/" rel="nofollow" target="_blank">Cardiovascular Disease Risk May Be Associated With Cancer Risk</a>

Sequence of Therapies for Metastatic Castration-Resistant Prostate Cancer

This week, we discuss two studies in genitourinary cancers presented at the ESMO Congress 2019. The CARD trial investigated treatment with cabazitaxel vs an androgen signaling–targeted inhibitor among patients with metastatic castration-resistant prostate cancer who had disease progression on docetaxel and the alternative androgen signaling–targeted inhibitor. The IMvigor130 trial focused on the efficacy and safety of atezolizumab as monotherapy or combined with platinum-based chemotherapy vs placebo plus platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.Coverage of stories discussed this week on ascopost.com:ESMO 2019: Cabazitaxel vs Abiraterone or Enzalutamide in Previously Treated Metastatic Castration-Resistant Prostate CancerESMO 2019: IMvigor130: Addition of Atezolizumab to Platinum-Based Chemotherapy in Advanced Urothelial Carcinoma

This week, we discuss two studies in genitourinary cancers presented at the ESMO Congress 2019. The CARD trial investigated treatment with cabazitaxel vs an androgen signaling–targeted inhibitor among patients with metastatic castration-resistant prostate cancer who had disease progression on docetaxel and the alternative androgen signaling–targeted inhibitor. The IMvigor130 trial focused on the efficacy and safety of atezolizumab as monotherapy or combined with platinum-based chemotherapy vs placebo plus platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/news/october-2019/cabazitaxel-vs-abiraterone-or-enzalutamide-in-previously-treated-mcrpc/" rel="nofollow" target="_blank">ESMO 2019: Cabazitaxel vs Abiraterone or Enzalutamide in Previously Treated Metastatic Castration-Resistant Prostate Cancer</a><a href="https://ascopost.com/news/october-2019/addition-of-atezolizumab-to-platinum-based-chemotherapy-in-advanced-urothelial-carcinoma/" rel="nofollow" target="_blank">ESMO 2019: IMvigor130: Addition of Atezolizumab to Platinum-Based Chemotherapy in Advanced Urothelial Carcinoma</a>

News in Genitourinary Cancers From ESMO 2019

This week, we discuss two studies in gastrointestinal cancers presented at this year’s European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in patients with locally advanced pancreatic cancer. Next, we’ll discuss the ClarIDHy study, which examined treatment with ivosidenib in patients with advanced cholangiocarcinoma and an IDH1 mutation. We’ll hear from the lead authors of each of these studies, and we’ll also hear a discussion about the use of cabozantinib in advanced hepatocellular carcinoma, with Dr. Tim Meyer and Dr. Lorenza Rimassa, co-investigators for the CELESTIAL trial.Coverage of stories discussed this week on ascopost.com:ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic CancerESMO 2019: Ivosidenib in IDH1-Mutated Advanced Cholangiocarcinoma

This week, we discuss two studies in gastrointestinal cancers presented at this year’s European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in patients with locally advanced pancreatic cancer. Next, we’ll discuss the ClarIDHy study, which examined treatment with ivosidenib in patients with advanced cholangiocarcinoma and an IDH1 mutation. We’ll hear from the lead authors of each of these studies, and we’ll also hear a discussion about the use of cabozantinib in advanced hepatocellular carcinoma, with Dr. Tim Meyer and Dr. Lorenza Rimassa, co-investigators for the CELESTIAL trial.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>: <a href="https://ascopost.com/news/october-2019/high-conversion-rate-with-certain-induction-chemotherapy-regimens-is-associated-with-improved-os-in-lapc/" rel="nofollow" target="_blank">ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer</a><a href="https://ascopost.com/news/october-2019/ivosidenib-in-idh1-mutated-advanced-cholangiocarcinoma/" rel="nofollow" target="_blank">ESMO 2019: Ivosidenib in </a><a href="https://ascopost.com/news/october-2019/ivosidenib-in-idh1-mutated-advanced-cholangiocarcinoma/" rel="nofollow" target="_blank">IDH1</a><a href="https://ascopost.com/news/october-2019/ivosidenib-in-idh1-mutated-advanced-cholangiocarcinoma/" rel="nofollow" target="_blank">-Mutated Advanced Cholangiocarcinoma</a>

Gastrointestinal Cancer Research From ESMO 2019

On this episode, we hear from the authors of three high-impact abstracts presented at the 2019 ASH Annual Meeting &amp; Exposition. The first paper investigated immunotherapy vs standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia; the second focused on the efficacy of oral azacitidine for acute myeloid leukemia; and the third looked at a triplet regimen for relapsed or refractory multiple myeloma.

On this episode, we hear from the authors of three high-impact abstracts presented at the 2019 ASH Annual Meeting &amp; Exposition. The first paper investigated immunotherapy vs standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia; the second focused on the efficacy of oral azacitidine for acute myeloid leukemia; and the third looked at a triplet regimen for relapsed or refractory multiple myeloma.

Plenary Presentations From the 2019 ASH Annual Meeting & Exposition

This week, we’ll be discussing research highlights in lung cancer presented at the ESMO Congress 2019, including the FLAURA trial of osimertinib in EGFR-mutated non–small cell lung cancer; the CheckMate 227 of nivolumab plus ipilimumab vs chemotherapy in non–small cell lung cancer with a PD-L1 expression of 1% or more; and the ASCEND-7 trial of ceritinib for ALK-positive non–small cell lung cancer that has spread to the brain.Coverage of stories discussed this week on ascopost.com:ESMO 2019: Overall Survival With Immunotherapy Doublet vs Chemotherapy in Advanced NSCLCESMO 2019: ASCEND-7: Ceritinib for Patients With ALK-Positive NSCLC Metastatic to the Brain

This week, we’ll be discussing research highlights in lung cancer presented at the ESMO Congress 2019, including the FLAURA trial of osimertinib in EGFR-mutated non–small cell lung cancer; the CheckMate 227 of nivolumab plus ipilimumab vs chemotherapy in non–small cell lung cancer with a PD-L1 expression of 1% or more; and the ASCEND-7 trial of ceritinib for ALK-positive non–small cell lung cancer that has spread to the brain.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>: <a href="https://ascopost.com/news/october-2019/overall-survival-with-nivolumabipilimumab-vs-chemotherapy-in-advanced-nsclc/" rel="nofollow" target="_blank">ESMO 2019: Overall Survival With Immunotherapy Doublet vs Chemotherapy in Advanced NSCLC</a><a href="https://ascopost.com/news/october-2019/ceritinib-for-patients-with-alk-positive-nsclc-metastatic-to-the-brain/" rel="nofollow" target="_blank">ESMO 2019: ASCEND-7: Ceritinib for Patients With ALK-Positive NSCLC Metastatic to the Brain</a>

Lung Cancer Research Highlights From ESMO 2019

This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries. Coverage of stories discussed this week on ascopost.com:Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLLCancer in Adults Aged 85 and Older: Rates, Screening, and SurvivalCMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries

This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries. Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>: <a href="https://ascopost.com/News/60318" rel="nofollow" target="_blank">Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL</a><a href="https://ascopost.com/News/60331" rel="nofollow" target="_blank">Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival</a><a href="https://ascopost.com/News/60327" rel="nofollow" target="_blank">CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries</a>

Ibrutinib and Rituximab vs Standard Chemoimmunotherapy in CLL

This week, we review a pooled analysis of long-term survival rates in patients with previously treated non–small cell lung cancer treated with nivolumab. We then turn to the recently reported USPSTF recommendation on risk assessment, genetic counseling, and genetic testing for BRCA1 or BRCA2 mutations. Lastly, we discuss the recent FDA approval of entrectinib for NTRK-fusion cancers and ROS1-positive NSCLC.Coverage of stories discussed this week on ascopost.com:Pooled Analysis of 4-Year Survival With Nivolumab Therapy in Patients With Previously Treated Advanced NSCLCUSPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related CancerFDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC

This week, we review a pooled analysis of long-term survival rates in patients with previously treated non–small cell lung cancer treated with nivolumab. We then turn to the recently reported USPSTF recommendation on risk assessment, genetic counseling, and genetic testing for BRCA1 or BRCA2 mutations. Lastly, we discuss the recent FDA approval of entrectinib for NTRK-fusion cancers and ROS1-positive NSCLC.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/News/60360" rel="nofollow" target="_blank">Pooled Analysis of 4-Year Survival With Nivolumab Therapy in Patients With Previously Treated Advanced NSCLC</a><a href="https://ascopost.com/News/60373" rel="nofollow" target="_blank">USPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for </a><a href="https://ascopost.com/News/60373" rel="nofollow" target="_blank">BRCA</a><a href="https://ascopost.com/News/60373" rel="nofollow" target="_blank">-Related Cancer</a><a href="https://ascopost.com/News/60351" rel="nofollow" target="_blank">FDA Approves Entrectinib for</a><a href="https://ascopost.com/News/60351" rel="nofollow" target="_blank"> NTRK</a><a href="https://ascopost.com/News/60351" rel="nofollow" target="_blank">-Fusion Cancers, </a><a href="https://ascopost.com/News/60351" rel="nofollow" target="_blank">ROS1</a><a href="https://ascopost.com/News/60351" rel="nofollow" target="_blank">-Positive NSCLC</a>

Pooled Survival Analysis of Patients With NSCLC Treated With Nivolumab

In this episode, we discuss more news from the ASCO Annual Meeting, including  findings from a study with relevance to surgical oncology, a summary of a study in HER2-positive breast cancer, and a third study on discrimination among hem/onc fellows. We also discuss two FDA approvals which took place in the last week.Coverage of stories discussed this week on ascopost.com:Discrimination, Gender Bias in Oncology Training and Professional MeetingsFDA Approves New Trastuzumab BiosimilarFDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies

In this episode, we discuss more news from the ASCO Annual Meeting, including findings from a study with relevance to surgical oncology, a summary of a study in HER2-positive breast cancer, and a third study on discrimination among hem/onc fellows. We also discuss two FDA approvals which took place in the last week.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>: <a href="https://www.ascopost.com/News/60132" rel="nofollow" target="_blank">Discrimination, Gender Bias in Oncology Training and Professional Meetings</a><a href="https://www.ascopost.com/News/60150" rel="nofollow" target="_blank">FDA Approves New Trastuzumab Biosimilar</a><a href="https://www.ascopost.com/News/60162" rel="nofollow" target="_blank">FDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies</a>

2019 ASCO: Resection of Liver Metastases

According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology. Next, we’ll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we’ll discuss two recent FDA drug approvals for patients with hematologic disorders.Coverage of stories discussed this week on ascopost.com:Nivolumab Plus Bevacizumab in Relapsed Ovarian CancerWhat Is the Best Palliation for End-Stage Lung Cancer?FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell LymphomaFDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia

According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in JAMA Oncology. Next, we’ll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we’ll discuss two recent FDA drug approvals for patients with hematologic disorders.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/news/november-2019/nivolumab-plus-bevacizumab-in-relapsed-ovarian-cancer/" rel="nofollow" target="_blank">Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer</a><a href="https://ascopost.com/news/november-2019/what-is-the-best-palliation-for-end-stage-lung-cancer/" rel="nofollow" target="_blank">What Is the Best Palliation for End-Stage Lung Cancer?</a><a href="https://ascopost.com/news/november-2019/fda-grants-accelerated-approval-to-zanubrutinib-for-pretreated-mantle-cell-lymphoma/" rel="nofollow" target="_blank">FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma</a><a href="https://ascopost.com/news/november-2019/fda-approves-luspatercept-aamt-for-anemia-in-patients-with-beta-thalassemia/" rel="nofollow" target="_blank">FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia</a>

Nivolumab Plus Bevacizumab for Relapsed Ovarian Cancer

This week, we’ll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We’ll also review the FDA’s approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.Coverage of stories discussed this week on ascopost.com:FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma

This week, we’ll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We’ll also review the FDA’s approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://www.ascopost.com/news/march-2020/fda-approves-isatuximab-irfc-based-triplet-regimen-for-patients-with-relapsed-and-refractory-multiple-myeloma/" rel="nofollow" target="_blank">FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma</a>

News From the 2020 Multidisciplinary Head and Neck Cancers Symposium

In this episode, The ASCO Post's Editor-in-Chief Dr. James Armitage talks about the International Conference on Malignant Lymphoma (ICML), which he attended recently in Lugano, Switzerland; in particular, Dr. Armitage shares insight from a workshop on bridging liquid biopsy into the management of patients with lymphoma. He also discusses two studies from the plenary session looking at the impact of adding lenalidomide to R-CHOP in the management of diffuse large B-cell lymphoma. Later in the podcast, we discuss findings from the PHARE trial on adjuvant trastuzumab dosing in HER2-positive breast cancer and we report two recent approvals by the FDA.Coverage of stories discussed this week on ascopost.com:Final Analysis of the PHARE Trial: 6 Months vs 12 Months of Adjuvant Trastuzumab in HER2-Positive Breast CancerFDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed, Transplant-Ineligible Patients With Multiple MyelomaFDA Approves Bevacizumab Biosimilar for Five Cancer Types

In this episode, The ASCO Post's Editor-in-Chief Dr. James Armitage talks about the International Conference on Malignant Lymphoma (ICML), which he attended recently in Lugano, Switzerland; in particular, Dr. Armitage shares insight from a workshop on bridging liquid biopsy into the management of patients with lymphoma. He also discusses two studies from the plenary session looking at the impact of adding lenalidomide to R-CHOP in the management of diffuse large B-cell lymphoma. Later in the podcast, we discuss findings from the PHARE trial on adjuvant trastuzumab dosing in HER2-positive breast cancer and we report two recent approvals by the FDA.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/News/60194" rel="nofollow" target="_blank">Final Analysis of the PHARE Trial: 6 Months vs 12 Months of Adjuvant Trastuzumab in HER2-Positive Breast Cancer</a><a href="https://ascopost.com/News/60199" rel="nofollow" target="_blank">FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed, Transplant-Ineligible Patients With Multiple Myeloma</a><a href="https://ascopost.com/News/60204" rel="nofollow" target="_blank">FDA Approves Bevacizumab Biosimilar for Five Cancer Types</a>

ICML 2019: Role of Liquid Biopsy in Lymphoma

This week, we’ll be going over news from the ASTRO Annual Meeting, including an analysis of the effect of long-term hormonal therapy on men with low PSA levels treated with early salvage radiotherapy after radical prostatectomy and an update on the landmark PACIFIC trial in non–small cell lung cancer. We also discuss the launch of Project Orbis, which led to a joint approval from the FDA, the Australian Therapeutic Goods Administration, and Health Canada for lenvatinib in combination with pembrolizumab in the treatment of some patients with advanced endometrial carcinoma.Coverage of stories discussed this week on ascopost.com:ASTRO 2019: Long-Term Hormone Therapy May Increase Other-Cause Mortality in Men With Prostate Cancer Receiving Early Salvage RadiotherapyASTRO 2019: Patterns of Disease Progression in Patients With Unresectable Stage III NSCLC: Analysis of the PACIFIC TrialFDA Grants Approval to Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer, Announces Project Orbis

This week, we’ll be going over news from the ASTRO Annual Meeting, including an analysis of the effect of long-term hormonal therapy on men with low PSA levels treated with early salvage radiotherapy after radical prostatectomy and an update on the landmark PACIFIC trial in non–small cell lung cancer. We also discuss the launch of Project Orbis, which led to a joint approval from the FDA, the Australian Therapeutic Goods Administration, and Health Canada for lenvatinib in combination with pembrolizumab in the treatment of some patients with advanced endometrial carcinoma.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/news/september-2019/long-term-hormone-therapy-in-men-with-prostate-cancer-receiving-early-salvage-radiotherapy/" rel="nofollow" target="_blank">ASTRO 2019: Long-Term Hormone Therapy May Increase Other-Cause Mortality in Men With Prostate Cancer Receiving Early Salvage Radiotherapy</a><a href="https://ascopost.com/news/september-2019/patterns-of-disease-progression-in-patients-with-unresectable-stage-iii-nsclc/l" rel="nofollow" target="_blank">ASTRO 2019: Patterns of Disease Progression in Patients With Unresectable Stage III NSCLC: Analysis of the PACIFIC Trial</a><a href="https://ascopost.com/news/september-2019/fda-grants-approval-to-lenvatinibpembrolizumab-in-advanced-endometrial-cancer-announces-project-orbis/" rel="nofollow" target="_blank">FDA Grants Approval to Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer, Announces Project Orbis</a>

News From the ASTRO Annual Meeting

This week, we’ll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we’ll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we’ll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.Coverage of stories discussed this week on ascopost.com:Extended Follow-up of CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib as First-Line Treatment for Advanced RCCKey Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer TypesExposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students

This week, we’ll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we’ll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we’ll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>: <a href="https://ascopost.com/news/august-2019/nivolumab-plus-ipilimumab-vs-sunitinib-as-first-line-treatment-for-advanced-rcc/" rel="nofollow" target="_blank">Extended Follow-up of CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib as First-Line Treatment for Advanced RCC</a> <a href="https://ascopost.com/news/august-2019/key-predictors-of-response-rates-to-pd1-and-pdl1-inhibitors/" rel="nofollow" target="_blank">Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types</a><a href="https://ascopost.com/news/august-2019/exposure-to-second-hand-e-cigarette-aerosols-increasing-among-students/" rel="nofollow" target="_blank">Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students</a>

First-Line Nivolumab and Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma

This week, we’ll review an interim analysis of the CASPIAN trial, which evaluated the addition of durvalumab to etoposide plus platinum chemotherapy for extensive-stage small cell lung cancer. Then, we’ll talk about two recently issued guidelines on screening for colorectal cancer. Lastly, we’ll summarize some recent FDA approvals and announcements.Coverage of stories discussed this week on ascopost.com:CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Extensive-Stage SCLCColorectal Cancer Screening With Fecal Immunochemical Testing, Sigmoidoscopy, or Colonoscopy for Patients Aged 50 to 79 Years OldAmerican College of Physicians Issues Guidance on Colorectal Cancer Screening for Average-Risk, Asymptomatic Adults Aged 50 to 75 YearsFDA Approves Pegfilgrastim BiosimilarFDA Approves Niraparib for Patients With Homologous Recombination Deficiency–Positive Advanced Ovarian CancerFDA Approves Daratumumab Combination for Transplant-Eligible Patients With Multiple MyelomaStephen Hahn, MD, to Be Nominated FDA Commissioner

This week, we’ll review an interim analysis of the CASPIAN trial, which evaluated the addition of durvalumab to etoposide plus platinum chemotherapy for extensive-stage small cell lung cancer. Then, we’ll talk about two recently issued guidelines on screening for colorectal cancer. Lastly, we’ll summarize some recent FDA approvals and announcements.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>: <a href="https://ascopost.com/news/october-2019/durvalumab-plus-platinumetoposide-for-first-line-treatment-of-extensive-stage-sclc/" rel="nofollow" target="_blank">CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Extensive-Stage SCLC</a><a href="https://ascopost.com/news/october-2019/colorectal-cancer-screening-guideline-for-patients-aged-50-to-79-years-old/" rel="nofollow" target="_blank">Colorectal Cancer Screening With Fecal Immunochemical Testing, Sigmoidoscopy, or Colonoscopy for Patients Aged 50 to 79 Years Old</a><a href="https://ascopost.com/news/november-2019/acp-issues-guidance-on-colorectal-cancer-screening/" rel="nofollow" target="_blank">American College of Physicians Issues Guidance on Colorectal Cancer Screening for Average-Risk, Asymptomatic Adults Aged 50 to 75 Years</a><a href="https://ascopost.com/news/november-2019/fda-approves-pegfilgrastim-biosimilar/" rel="nofollow" target="_blank">FDA Approves Pegfilgrastim Biosimilar</a><a href="https://ascopost.com/news/october-2019/fda-approves-niraparib-for-patients-with-hrd-positive-advanced-ovarian-cancer/" rel="nofollow" target="_blank">FDA Approves Niraparib for Patients With Homologous Recombination Deficiency–Positive Advanced Ovarian Cancer</a><a href="https://ascopost.com/issues/october-10-2019/fda-approves-daratumumab-for-transplant-eligible-multiple-myeloma/" rel="nofollow" target="_blank">FDA Approves Daratumumab Combination for Transplant-Eligible Patients With Multiple Myeloma</a> <a href="https://ascopost.com/news/november-2019/stephen-hahn-md-to-be-nominated-fda-commissioner/" rel="nofollow" target="_blank">Stephen Hahn, MD, to Be Nominated FDA Commissioner</a>

Addition of Durvalumab to Etoposide Plus Platinum Chemotherapy for Extensive-Stage SCLC

The FDA certainly had a busy December, and this week, we’ll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki  for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and  atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic CancerFDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast CancerFDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial CancerFDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate CancerFDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer

The FDA certainly had a busy December, and this week, we’ll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/news/january-2020/fda-approves-olaparib-for-patients-with-germline-brca-mutated-metastatic-pancreatic-cancer/" rel="nofollow" target="_blank">FDA Approves Olaparib for Patients With Germline</a><a href="https://ascopost.com/news/january-2020/fda-approves-olaparib-for-patients-with-germline-brca-mutated-metastatic-pancreatic-cancer/" rel="nofollow" target="_blank"> BRCA</a><a href="https://ascopost.com/news/january-2020/fda-approves-olaparib-for-patients-with-germline-brca-mutated-metastatic-pancreatic-cancer/" rel="nofollow" target="_blank">-Mutated Metastatic Pancreatic Cancer</a><a href="https://ascopost.com/news/december-2019/fda-approves-fam-trastuzumab-deruxtecan-nxki-for-patients-with-unresectable-or-metastatic-her2-positive-breast-cancer/" rel="nofollow" target="_blank">FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer</a><a href="https://ascopost.com/news/december-2019/fda-approves-enfortumab-vedotin-ejfv-for-previously-treated-advanced-urothelial-cancer/" rel="nofollow" target="_blank">FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer</a><a href="https://ascopost.com/news/december-2019/fda-approves-enzalutamide-for-patients-with-metastatic-castration-sensitive-prostate-cancer/" rel="nofollow" target="_blank">FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer</a><a href="https://ascopost.com/issues/december-10-2019/fda-approves-pd-l1-inhibitor-plus-chemotherapy-for-first-line-treatment-of-metastatic-nonsquamous-non-small-cell-lung-cancer/" rel="nofollow" target="_blank">FDA Approves PD-L1 Inhibitor Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer</a>

Recent Approvals From the FDA

This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We’ll also discuss last week’s FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.Coverage of stories discussed this week on ascopost.com:ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular CarcinomaESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast CancerFDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis

This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We’ll also discuss last week’s FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://ascopost.com/news/november-2019/combination-of-atezolizumab-and-bevacizumab-for-unresectable-hcc/" rel="nofollow" target="_blank">ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma</a><a href="https://ascopost.com/news/november-2019/trastuzumab-biosimilar-hlx02-shows-activity-in-her2-positive-metastatic-breast-cancer/" rel="nofollow" target="_blank">ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer</a><a href="https://ascopost.com/news/november-2019/fda-approves-acalabrutinib-for-cllsll-as-part-of-project-orbis/" rel="nofollow" target="_blank">FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis</a>

Reports From the ESMO Asia Congress 2019

In this episode, we discuss news from the Annual Congress of the European Hematology Association in multiple myeloma, catch up on a study presented at ASCO on gastric cancer, and review a recently published paper on prostate cancer development in World Trade Center first responders.Coverage of stories discussed this week on ascopost.com:EHA 2019: CASSIOPEIA Trial Examines Addition of Daratumumab to Standard Treatment Before and After ASCT in Multiple MyelomaExposure to Specific Carcinogens and Prostate Cancer Risk Among World Trade Center First Responders

In this episode, we discuss news from the Annual Congress of the European Hematology Association in multiple myeloma, catch up on a study presented at ASCO on gastric cancer, and review a recently published paper on prostate cancer development in World Trade Center first responders.Coverage of stories discussed this week on <a href="http://ascopost.com" rel="nofollow" target="_blank">ascopost.com</a>:<a href="https://www.ascopost.com/News/60163" rel="nofollow" target="_blank">EHA 2019: CASSIOPEIA Trial Examines Addition of Daratumumab to Standard Treatment Before and After ASCT in Multiple Myeloma</a><a href="https://www.ascopost.com/News/60186" rel="nofollow" target="_blank">Exposure to Specific Carcinogens and Prostate Cancer Risk Among World Trade Center First Responders</a>

CASSIOPEIA Trial in Multiple Myeloma

The best podcast episodes about true crime. For any thrill seeking podcast listeners who just can't get enough of the captivating stories of murderers and criminals. This topic has all the best episodes from many different true crime podcasts.  Add episodes you're interested into your queue below!

Best True Crime Podcasts

The best podcasts on investing. For anyone interested in the stories in the investing industry, whether it's an interview with Ray Dalio or Ed Thorp to the writer of The Big Short. This topic includes the most fascinating stories from all the best investors. Add episodes you're interested into your queue below!